HOLX
Hologic, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$76.01
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.1B | 4.1B | 4.0B | 4.0B | 4.9B |
| Cost of Revenue | 1.9B | 1.6B | 1.8B | 2.0B | 1.9B |
| Gross Profit | 2.2B | 2.5B | 2.2B | 2.1B | 3.0B |
| Operating Expenses | |||||
| R&D Expense | 248.5M | 248.2M | 272.8M | 294.3M | 283.4M |
| SG&A Expense | 1.1B | 1.1B | 994.8M | 987.6M | 1.0B |
| General & Admin Expense | 461.4M | 449.3M | 409.4M | 392.4M | 407.7M |
| Selling & Marketing Expense | 609.3M | 620.6M | 585.4M | 595.2M | 630.3M |
| Other Expenses | 138.6M | 468.7M | 77.6M | 121.2M | 35.8M |
| Total Operating Expenses | 1.5B | 1.8B | 1.3B | 1.4B | 1.4B |
| Cost and Expenses | 3.4B | 3.4B | 3.1B | 3.4B | 3.2B |
| Operating Income (EBIT) | 721.6M | 714.3M | 882.6M | 668.4M | 1.6B |
| Non-Operating | |||||
| Interest Income | 69.9M | 74.4M | 108.7M | 120.5M | 12.9M |
| Interest Expense | 95.2M | 42.7M | 122.1M | 111.1M | 95.1M |
| Net Interest Income | (25.3M) | 31.7M | (13.4M) | 9.4M | (82.2M) |
| Other Non-Op Income/Expense | (58.0M) | (33.1M) | (17.5M) | 7.7M | (52.0M) |
| Non-Operating Income (excl Interest) | (40.2M) | (9.6M) | (104.6M) | (118.8M) | (43.1M) |
| EBT (Pre-Tax Income) | 663.6M | 681.2M | 865.1M | 676.1M | 1.6B |
| Income Tax Expense | 119.7M | 115.5M | 75.6M | 220.1M | 286.2M |
| Bottom Line | |||||
| Net Income | 543.9M | 565.7M | 789.5M | 456.0M | 1.3B |
| Earnings from Cont. Ops | 543.9M | 565.7M | 789.5M | 456.0M | 1.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 543.9M | 565.7M | 789.5M | 456.0M | 1.3B |
| Per Share | |||||
| Basic EPS | $2.43 | $2.50 | $3.35 | $1.85 | $5.18 |
| Diluted EPS | $2.40 | $2.49 | $3.32 | $1.83 | $5.13 |
| Revenue Per Share | $18.39 | $18.05 | $17.10 | $16.33 | $19.33 |
| Shares | |||||
| Basic Shares Outstanding | 224.4M | 227.2M | 235.7M | 246.8M | 251.5M |
| Diluted Shares Outstanding | 225.9M | 227.6M | 237.6M | 248.8M | 253.8M |
| Profitability Metrics | |||||
| EBITDA | 1.0B | 1.0B | 1.3B | 1.1B | 2.1B |
| D&A | 252.1M | 299.8M | 309.0M | 323.4M | 430.1M |
| EBIT | 761.8M | 723.9M | 987.2M | 787.2M | 1.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025